William G. Ondo VIEW CLINICAL PROFILE

William G. Ondo, MD

Professor of Neurology, Academic Institute
Full Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


VIEW CLINICAL PROFILE
Biography

Dr. William G. Ondo is the director of the Movement Disorders Clinic at the Houston Methodist Neurological Institute. Dr. Ondo has been in practice for nearly 20 years and specializes in diagnosis, treatment and research of Parkinson’s disease, essential tremors, the use of botulinum toxins in treating movement disorders, and restless legs syndrome.

Dr. Ondo earned his medical degree from the Medical College of Virginia before completing an internship at the University of North Carolina Hospital, a neurology residency at Duke University, and a movement disorders fellowship at the Baylor College of Medicine. He is board certified by the American Board of Psychiatry and Neurology in adult neurology and sleep medicine. He has authored more than 250 original articles and book chapters as well as edited two books on movement disorders. He currently serves as the president of the Tremor Research Group.

Areas Of Expertise

Ataxia Parkinson's disease Dystonia Essential tremor Restless legs
Active Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

NCT04201093


A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

NCT03655236

Publications

The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia
Trosch, RM, Comella, CL, Caroff, SN, Ondo, WG, Shillington, AC, LaChappelle, BJ, Hauser, RA, Correll, CU & Friedman, JH 2024, , The Journal of clinical psychiatry, vol. 85, no. 1. https://doi.org/10.4088/JCP.23m14886

Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome
Walters, AS, Li, Y, Koo, BB, Ondo, WG, Weinstock, LB, Champion, D, Afrin, LB, Karroum, EG, Bagai, K & Spruyt, K 2024, , Brain, vol. 147, no. 1, pp. 26-38. https://doi.org/10.1093/brain/awad283

A Randomized Phase 2 KINETIC Trial Evaluating SAGE-324/BIIB124 in Individuals with Essential Tremor
Elble, RJ, Ondo, WG, Lyons, KE, Qin, M, Garafola, S, Hersh, B, Lieu, TM, Arkilo, D, Chuang, R, Bankole, K & Pahwa, R 2024, , Movement Disorders. https://doi.org/10.1002/mds.29731

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)
Koneru, V, Espay, AJ, Cole, AJ, Weintraub, D, Crist, K, Pascual, MB & Ondo, WG 2023, , Movement disorders : official journal of the Movement Disorder Society, vol. 38, no. 11, pp. 1982-1987. https://doi.org/10.1002/mds.29627

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
Hauser, RA, Espay, AJ, Ellenbogen, AL, Fernandez, HH, Isaacson, SH, Lewitt, PA, Ondo, WG, Pahwa, R, Schwarz, J, Stocchi, F, Zeitlin, L, Banisadr, G, Fisher, S, Visser, H & DSouza, R 2023, , JAMA Neurology, vol. 80, no. 10, pp. 1062-1069. https://doi.org/10.1001/jamaneurol.2023.2679

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
Huntington Study Group KINECT-HD Collaborators 2023, , The Lancet Neurology, vol. 22, no. 6, pp. 494-504. https://doi.org/10.1016/S1474-4422(23)00127-8

Dose Optimization of Apomorphine Sublingual Film for off Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Hauser, RA, Ondo, WG, Zhang, Y, Bowling, A, Navia, B, Pappert, E & Isaacson, SH 2023, , Journal of Parkinsons disease, vol. 13, no. 3, pp. 403-414. https://doi.org/10.3233/JPD-223537

Clozapine: Efficacy for Parkinson Disease psychosis in patients refractory to pimavanserin
Thames, BH & Ondo, WG 2023, , Parkinsonism and Related Disorders, vol. 109, 105356, pp. 105356. https://doi.org/10.1016/j.parkreldis.2023.105356

Task Specific Tremor in Parkinson’s Disease Responds to Apomorphine
Ondo, WG, Koneru, V & Arif, C 2023, , Tremor and Other Hyperkinetic Movements, vol. 13, no. 1, 20, pp. 20. https://doi.org/10.5334/tohm.764

The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP)
Koneru, V, Espay, AJ, Cole, AJ, Weintraub, D, Crist, K, Pascual, MB & Ondo, WG 2023, , Movement Disorders, vol. 38, no. 11, pp. 1982-1987. https://doi.org/10.1002/mds.29627

An Empirical Comparison of Commonly Used Universal Rating Scales for Dystonia
Boz, D, Kilic-Berkmen, G, Perlmutter, JS, Norris, SA, Wright, LJ, Klein, C, Bäumer, T, Löns, S, Feuerstein, JS, Mahajan, A, Wagle-Shukla, A, Malaty, I, LeDoux, MS, Ondo, W, Pantelyat, A, Frank, S, Saunders-Pullman, R & Jinnah, HA 2023, , Movement Disorders Clinical Practice, vol. 10, no. 12, pp. 1777-1786. https://doi.org/10.1002/mdc3.13909

Consensus guidelines on the construct validity of rodent models of restless legs syndrome
the International Restless Legs Syndrome Study Group (IRLSSG) 2022, , DMM Disease Models and Mechanisms, vol. 15, no. 8, dmm049615. https://doi.org/10.1242/dmm.049615

Tremor rating scales and laboratory tools for assessing tremor
Elble, RJ & Ondo, W 2022, , Journal of the Neurological Sciences, vol. 435, 120202, pp. 120202. https://doi.org/10.1016/j.jns.2022.120202

Stroke-related restless legs syndrome: epidemiology, clinical characteristics, and pathophysiology
Wang, XX, Feng, Y, Tan, EK, Ondo, WG & Wu, YC 2022, , Sleep Medicine, vol. 90, pp. 238-248. https://doi.org/10.1016/j.sleep.2022.02.001

Enhancing GABA inhibition is the next generation of medications for essential tremor
Ondo, W 2022, . in S-H Kuo & ED Louis (eds), Essential Tremor: Current Concepts and Controversies. vol. 163, International review of neurobiology, Academic Press, pp. 317-334. https://doi.org/10.1016/bs.irn.2022.02.007

Facial Myokymia and Hemimasticatory Spasm with Linear Focal Alopecia
Koneru, V & Ondo, WG 2023, , Movement Disorders Clinical Practice, vol. 10, no. 1, pp. 143-144. https://doi.org/10.1002/mdc3.13602

We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments
Fulda, S, Allen, RP, Earley, CJ, Högl, B, Garcia-Borreguero, D, Inoue, Y, Ondo, W, Walters, AS, Williams, AM & Winkelman, JW 2021, , Sleep Medicine Reviews, vol. 58, 101461. https://doi.org/10.1016/j.smrv.2021.101461

The Management of Restless Legs Syndrome: An Updated Algorithm
Scientific and Medical Advisory Board of the Restless Legs Syndrome Foundation 2021, , Mayo Clinic Proceedings, vol. 96, no. 7, pp. 1921-1937. https://doi.org/10.1016/j.mayocp.2020.12.026

Correction: Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Patel, AT, Lew, MF, Dashtipour, K, Isaacson, S, Hauser, RA, Ondo, W, Maisonobe, P, Wietek, S, Rubin, B & Brashear, A 2021, , PLoS ONE, vol. 16, no. 4, e0250475, pp. e0250475. https://doi.org/10.1371/journal.pone.0250475

Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study
Patel, AT, Lew, MF, Dashtipour, K, Isaacson, S, Hauser, RA, Ondo, W, Maisonobe, P, Wietek, S, Rubin, B & Brashear, A 2021, , PLoS ONE, vol. 16, no. 2 February, e0245827. https://doi.org/10.1371/journal.pone.0245827

VIEW FULL PUBLICATIONS